SRNE has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
SRNE has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Sorrento Therapeutics's annualized Net Income for the quarter that ended in Jun. 2023 was $-380.85 Mil. Sorrento Therapeutics's average total tangible assets for the quarter that ended in Jun. 2023 was $255.03 Mil. Therefore, Sorrento Therapeutics's annualized Return-on-Tangible-Asset for the quarter that ended in Jun. 2023 was -149.33%.
The historical rank and industry rank for Sorrento Therapeutics's Return-on-Tangible-Asset or its related term are showing as below:
During the past 13 years, Sorrento Therapeutics's highest Return-on-Tangible-Asset was 2.96%. The lowest was -187.43%. And the median was -54.12%.
The historical data trend for Sorrento Therapeutics's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sorrento Therapeutics Annual Data | |||||||||||||||||||||
Trend | Dec13 | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | |||||||||||
Return-on-Tangible-Asset | Get a 7-Day Free Trial | -48.36 | -59.88 | -68.25 | -110.65 | -187.43 |
Sorrento Therapeutics Quarterly Data | ||||||||||||||||||||
Sep18 | Dec18 | Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | |
Return-on-Tangible-Asset | Get a 7-Day Free Trial | -195.40 | -96.55 | -288.80 | -218.33 | -149.33 |
For the Biotechnology subindustry, Sorrento Therapeutics's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Sorrento Therapeutics's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Sorrento Therapeutics's Return-on-Tangible-Asset falls into.
Sorrento Therapeutics's annualized Return-on-Tangible-Asset for the fiscal year that ended in Dec. 2022 is calculated as:
Return-on-Tangible-Asset | = | Net Income | / | ( (Total Tangible Assets | + | Total Tangible Assets) | / count ) |
(A: Dec. 2022 ) | (A: Dec. 2021 ) | (A: Dec. 2022 ) | |||||
= | Net Income | / | ( (Total Assets - Intangible Assets | + | Total Assets - Intangible Assets) | / count ) | |
(A: Dec. 2022 ) | (A: Dec. 2021 ) | (A: Dec. 2022 ) | |||||
= | -572.843 | / | ( (355.588 | + | 255.669) | / 2 ) | |
= | -572.843 | / | 305.6285 | ||||
= | -187.43 % |
Sorrento Therapeutics's annualized Return-on-Tangible-Asset for the quarter that ended in Jun. 2023 is calculated as:
Return-on-Tangible-Asset | = | Net Income | / | ( (Total Tangible Assets | + | Total Tangible Assets) | / count ) |
(Q: Jun. 2023 ) | (Q: Mar. 2023 ) | (Q: Jun. 2023 ) | |||||
= | Net Income | / | ( (Total Assets - Intangible Assets | + | Total Assets - Intangible Assets) | / count ) | |
(Q: Jun. 2023 ) | (Q: Mar. 2023 ) | (Q: Jun. 2023 ) | |||||
= | -380.848 | / | ( (255.919 | + | 254.14) | / 2 ) | |
= | -380.848 | / | 255.0295 | ||||
= | -149.33 % |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Jun. 2023) net income data.
Sorrento Therapeutics (OTCPK:SRNE) Return-on-Tangible-Asset Explanation
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Thank you for viewing the detailed overview of Sorrento Therapeutics's Return-on-Tangible-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.
Henry Ji | director, officer: See Remarks | 5370 RUETTE DE MER, SAN DIEGO CA 92130 |
Tammy Reilly | director | C/O SORRENTO THERAPEUTICS, INC., 4955 DIRECTORS PLACE, SAN DIEGO CA 92121 |
Kim Janda | director | 6042 CORNERSTONE CT. WEST, SUITE B, SAN DIEGO CA 92121 |
Elizabeth Czerepak | director | 201 ROUTE 17 NORTH, RUTHERFORD NJ 07070 |
Dorman Followwill | director | C/O SORRENTO THERAPEUTICS, INC., 4955 DIRECTOR'S PLACE, SAN DIEGO CA 92121 |
Najjam Asghar | officer: Chief Financial Officer | C/O SORRENTO THERAPEUTICS, INC., 4955 DIRECTORS PLACE, SAN DIEGO CA 92121 |
Robin L Smith | director | C/O PHASE III MEDICAL, INC., 330 SOUTH SERVICE ROAD, SUITE 120, MELVILLE NY 11747 |
Edgar Lee | director | C/O OAKTREE CAPITAL MANAGEMENT, L.P., 333 SOUTH GRAND AVE, 28TH FLOOR, LOS ANGELES CA 90071 |
Jerome B Zeldis | officer: See Remarks | 8767 E. VIA DE VENTURA, SUITE 190, SCOTTSDALE AZ 85258 |
Jaisim Shah | director | C/O PROTINE DESIGN LAB, 37481 MARSTEN DR, NEWARK CA 94560 |
Yue Alexander Wu | director | C/O SORRENTO THERAPEUTICS, INC., 9380 JUDICIAL DRIVE, SAN DIEGO CA 92121 |
David Lemus | director | C/O SORRENTO THERAPEUTICS, INC., 4955 DIRECTOR'S PLACE, SAN DIEGO CA 92121 |
Abg Management Ltd | 10 percent owner | UNIT 3002-04,30TH FLOOR,GLOUCESTER TOWER, THE LANDMARK,15 QUEEN'S ROAD CENTRAL, HONG KONG K3 000000 |
Jiong Shao | officer: Chief Financial Officer | SUITE 1003-1004, 10/F, ICBC TOWER, THREE GARDEN ROAD, CENTRAL, HONG KONG F4 000000 |
George K Ng | officer: See Remarks | C/O SORRENTO THERAPEUTICS, INC., 6042 CORNERSTONE COURT WEST, SUITE B, SAN DIEGO CA 92121 |
From GuruFocus
By Value_Insider Value_Insider • 12-05-2022
By Stock market mentor Stock market mentor • 01-09-2023
By PRNewswire PRNewswire • 02-13-2023
By GuruFocus Research • 02-15-2024
By Stock market mentor Stock market mentor • 02-05-2023
By Marketwired • 09-07-2023
By Value_Insider Value_Insider • 11-29-2022
By PRNewswire • 08-08-2023
By PRNewswire PRNewswire • 02-22-2023
By sperokesalga sperokesalga • 02-19-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.